Physician profile
Michael Beattie
NPI 1306366133
$2,334.04
in general payments reported to CMS, 2019-2025
25 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2021: $142 · 2022: $426 · 2023: $152 · 2024: $679 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536 · Education: $20.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.24 |
| Education | $20.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.82 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.96 | 2019-2024 | Plenvu, Xifaxan |
| Intercept Pharmaceuticals, INC. | $108.39 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $106.79 | 2023-2025 | Voquezna |
| Janssen Biotech, INC. | $93.42 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Scientific Affairs, LLC | $88.74 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.20 | 2023-2025 | Entyvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.06 | 2021 | |
| Genzyme Corporation | $82.04 | 2025 | |
| Organon LLC | $72.75 | 2024-2025 | Hadlima |
| Qol Medical, LLC | $62.63 | 2025 | Sucraid |
| E.R. Squibb & Sons, L.L.C. | $58.90 | 2021 | |
| Lilly USA, LLC | $51.98 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $42.27 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $30.69 | 2025 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $26.73 | 2025 | Suflave, Sutab |
| Daiichi Sankyo INC. | $22.03 | 2024 | Injectafer |
| Celltrion USA INC. | $20.81 | 2024 | Zymfentra |
| Gilead Sciences, INC. | $18.98 | 2024 | |
| Madrigal Pharmaceuticals | $18.44 | 2025 | Rezdiffra |
| Pfizer INC. | $16.59 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.14 | 2023 | Rebyota |
| Boston Scientific Corporation | $15.72 | 2024 | Resolution 360 Clip |
| Celgene Corporation | $14.35 | 2024 | Zeposia |
| Exact Sciences Corporation | $13.61 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Beattie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.